A director at Generali sold 3,700 shares at 33.310EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2025 sowie Informationen zur Geschäftsentwicklung Weiterentwicklung der Onkologie-Pipeline vorangetrieben mit strategischem Fokus auf zwei tumorübergreifende (Pan-Tumor-)Programme: Immunmodulator-Kandidat BNT327, ein gegen PD-L1 und VEGF-A1 gerichteter bispezifischer Antikörper, und mRNA-Krebsimmuntherapie-Kandidaten BioNTechs Kombinationsstrategie in der Onkologie wurde anhand mehrerer klinischer Daten-Updates aus der Onkologie-Pipeline untermauert, unter anderem durch erste Daten für die innovative Kombination von BNT327 mit einem ...
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted ...
BioNTech ernennt Ramón Zapata zum neuen Finanzvorstand Mainz, Deutschland, 5. Mai 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ramón Zapata-Gomez mit Wirkung zum 1. Juli 2025 zum Finanzvorstand (Chief Financial Officer, „CFO“) ernannt hat. Er wechselt von der globalen biomedizinischen Forschungsorganisation der Novartis AG (Novartis Biomedical Research), wo er seit 2022 als CFO tätig war, zu BioNTech. Ramón Zapata tritt die Nachfolge von Jens Holstein an, der wie bereits angekündigt zum 30. Juni 2025 planmäßig aus dem Un...
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.